This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Exact Sciences (EXAS) Resumen de Acciones
Exact Sciences Corporation ofrece productos para pruebas de detección y diagnóstico del cáncer en Estados Unidos y a escala internacional. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 5/6 |
| Crecimiento futuro | 3/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 4/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
No se han detectado riesgos en EXAS a partir de nuestros controles de riesgos.
EXAS Community Fair Values
Create NarrativeSee what 57 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Exact Sciences Corporation
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$104.91 |
| Máximo en las últimas 52 semanas | US$104.98 |
| Mínimo de 52 semanas | US$38.81 |
| Beta | 1.44 |
| Cambio en 1 mes | 1.43% |
| Variación en 3 meses | 3.32% |
| Cambio de 1 año | 129.71% |
| Variación en 3 años | 58.26% |
| Variación en 5 años | -15.16% |
| Variación desde la OPV | 611.25% |
Noticias y actualizaciones recientes
Actualización del análisis • Mar 16
EXAS: Abbott Deal Expectations And Downgrades Will Shape Event Path Forward
The analyst price target for Exact Sciences has been adjusted to reflect a revised view of slightly higher long term revenue growth and profit margins, along with a modestly higher discount rate and a lower assumed future P/E multiple, resulting in a new target of $105.81, unchanged from the prior target of $105.81. Analyst Commentary Recent Street research around Exact Sciences has been limited, with one identified change being a downgrade and another reference tied to a broader sector view rather than company specific fundamentals.
Actualización del análisis • Mar 02
EXAS: Fair Value Reset Will Hinge On Abbott Deal And Margin Delivery
Analysts have trimmed their fair value estimate for Exact Sciences from $116.46 to $112.11. This reflects slightly lower modeled revenue growth, offset by a modestly higher profit margin outlook and a reduced future P/E assumption.Actualización del análisis • Feb 16
EXAS: Abbott Takeout Price And Downgrades Will Shape Event Path Forward
Analysts have maintained their $105 per share price target for Exact Sciences, with recent research emphasizing the agreed Abbott acquisition price of $105 as the key anchor for valuation and indicating limited expectations for additional upside. Analyst Commentary Recent research around Exact Sciences has shifted sharply toward viewing the agreed US$105 per share Abbott offer as the primary reference point for valuation, with many firms recalibrating their ratings and targets to that level.Recent updates
Actualización del análisis • Mar 16
EXAS: Abbott Deal Expectations And Downgrades Will Shape Event Path Forward
The analyst price target for Exact Sciences has been adjusted to reflect a revised view of slightly higher long term revenue growth and profit margins, along with a modestly higher discount rate and a lower assumed future P/E multiple, resulting in a new target of $105.81, unchanged from the prior target of $105.81. Analyst Commentary Recent Street research around Exact Sciences has been limited, with one identified change being a downgrade and another reference tied to a broader sector view rather than company specific fundamentals.Actualización del análisis • Mar 02
EXAS: Fair Value Reset Will Hinge On Abbott Deal And Margin Delivery
Analysts have trimmed their fair value estimate for Exact Sciences from $116.46 to $112.11. This reflects slightly lower modeled revenue growth, offset by a modestly higher profit margin outlook and a reduced future P/E assumption.Actualización del análisis • Feb 16
EXAS: Abbott Takeout Price And Downgrades Will Shape Event Path Forward
Analysts have maintained their $105 per share price target for Exact Sciences, with recent research emphasizing the agreed Abbott acquisition price of $105 as the key anchor for valuation and indicating limited expectations for additional upside. Analyst Commentary Recent research around Exact Sciences has shifted sharply toward viewing the agreed US$105 per share Abbott offer as the primary reference point for valuation, with many firms recalibrating their ratings and targets to that level.Actualización del análisis • Feb 02
EXAS: Takeout Premium And Downgrades Will Frame Upcoming Deal Closure Risk
Analysts made a modest upward adjustment to their fair value estimate for Exact Sciences to $105.81, describing it as largely in line with the $105 per share Abbott takeout price and supported by updated assumptions around discount rate, profit margin, and future P/E in recent research following the wave of rating downgrades tied to the announced acquisition. Analyst Commentary Street research around Exact Sciences has shifted quickly toward treating the shares as a deal proxy after the announced US$105 per share cash offer from Abbott.Actualización del análisis • Jan 19
EXAS: Abbott Takeover Agreement Will Anchor Upside To Deal Completion
Analysts have lifted their fair value estimate for Exact Sciences from $77.68 to $116.46. This reflects updated assumptions around slightly higher revenue growth, a revised profit margin outlook, a modestly higher discount rate, and a higher future P/E multiple in light of the agreed Abbott takeout price of $105 per share and the cluster of Street targets around that level.
Actualización del análisis • Jan 04
EXAS: Abbott Deal At $105 Will Define Shares With Balanced Prospects
Analysts have raised their price target on Exact Sciences to approximately $93 from about $48, citing the $105 per share Abbott takeout as validation of higher long term profitability and valuation multiples, despite slightly tempered standalone growth expectations. Analyst Commentary Bearish analysts largely framed the Abbott transaction as crystallizing value and limiting further upside, prompting a wave of rating downgrades to Hold, Neutral, Equal Weight, and Market Perform.Actualización del análisis • Dec 15
EXAS: Takeout Premium Will Shift Focus To Deal Completion Risk Balancing Upside
Analysts have raised their price targets on Exact Sciences toward the agreed Abbott takeout price of $105 per share. This reflects improved growth and margin expectations alongside the belief that the acquisition premium fairly captures the company’s long term value.Actualización del análisis • Dec 01
EXAS: Acquisition By Abbott Will Shift Focus Toward Deal Closure And Approval
The analyst price target for Exact Sciences has increased from $82.10 to $103.67 following the announcement of its acquisition by Abbott for $105 per share. Analysts cite the takeover premium and strong strategic rationale as key drivers behind the upward revision.Seeking Alpha • Nov 20
Abbott To Complete $21B M&A Deal For Exact Sciences - What Investors Should Know
Summary Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share, driven by Exact's cancer diagnostics leadership. Exact Sciences boasts strong revenue growth, record Q3 results, and promising new products like CancerGuard but remains unprofitable with fierce competition in cancer screening. Abbott Laboratories seeks to revitalize growth and expand its diagnostics portfolio, betting on Exact Sciences' MCED technology and established products like Cologuard despite high acquisition costs. Maintain Hold ratings on both Exact Sciences and Abbott Laboratories; Exact shareholders benefit from the deal, while Abbott's upside depends on successful integration and MCED market adoption. Read the full article on Seeking AlphaArtículo de análisis • Nov 20
Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Boosted 37% But Its Business Prospects Need A Lift Too
Despite an already strong run, Exact Sciences Corporation ( NASDAQ:EXAS ) shares have been powering on, with a gain of...Actualización del análisis • Nov 17
EXAS: Revenue Momentum And Expanded Guidance Will Drive Shares Higher
Analysts have raised their price target for Exact Sciences from approximately $70 to $82, citing stronger-than-expected revenue growth, margin expansion, and several upward revisions in expectations following earnings. Analyst Commentary Recent analyst updates reflect growing optimism about Exact Sciences' prospects, particularly in light of strong revenue growth, expanded guidance, and successful execution across its core business lines.Actualización del análisis • Nov 01
EXAS: Cancer Screening Expansion Will Balance Challenges From Blood Test Data
Analysts have raised their price target for Exact Sciences to $70 from $60, citing continued strength in its core Cologuard franchise as well as expanding opportunities in cancer screening and detection. Analyst Commentary Recent analyst activity for Exact Sciences reflects a dynamic mix of optimism and caution, as the company continues to execute on its core strengths while navigating evolving market expectations.Actualización del análisis • Oct 18
Humana, Centene And Medicare Coverage Will Increase Screening Access
Analysts have raised their price target for Exact Sciences to approximately $70 from $65, citing strong momentum from new revenue opportunities and increased confidence in long-term growth drivers. Analyst Commentary Recent analyst actions on Exact Sciences reflect notable shifts in sentiment, both positive and cautious, following the company’s latest performance and strategic moves.Actualización del análisis • Oct 03
Humana, Centene And Medicare Coverage Will Increase Screening Access
Analysts have modestly raised their price target for Exact Sciences, increasing it from $64.01 to $65.38. They cite incremental near-term revenue growth drivers, ongoing margin expansion, and improved cash flow prospects as key reasons for the upward adjustment.Actualización del análisis • Sep 12
Humana, Centene And Medicare Coverage Will Increase Screening Access
Analysts have modestly raised Exact Sciences’ price target to $64.01, citing renewed optimism from the Freenome deal and Shield V2 data as potential growth catalysts despite near-term skepticism around CRC blood-test data, resulting in only a slight upward revision to fair value. Analyst Commentary Bullish analysts cite the Freenome deal and Shield V2 data as catalysts for renewed Street focus on execution, with multiple near-term revenue growth drivers, continued EBITDA margin expansion, improving cash flow, and possible estimate upside.Artículo de análisis • Sep 08
Exact Sciences Corporation's (NASDAQ:EXAS) Price Is Right But Growth Is Lacking After Shares Rocket 31%
Exact Sciences Corporation ( NASDAQ:EXAS ) shareholders are no doubt pleased to see that the share price has bounced...Actualización del análisis • Aug 08
Humana, Centene And Medicare Coverage Will Increase Screening Access
Despite a slight rise in Exact Sciences’ future P/E ratio and a modest decline in its net profit margin, the consensus analyst price target remains unchanged at $64.60. What's in the News Exact Sciences raised full-year 2025 revenue guidance to $3.13–$3.17 billion, up from previous estimates of $3.07–$3.12 billion, reflecting strong business momentum (Key Developments, 2025-08-06).
Nuevo análisis • Apr 27
Cologuard Plus And Oncodetect Will Improve Cancer Screening Outcomes
Cologuard Plus and rescreening efforts are key drivers of revenue growth, bolstered by payer coverage and an increasing pool of eligible individuals.Seeking Alpha • Aug 18
Exact Sciences: Cost Optimization And Product Strength
Summary Exact Sciences stock is down 35% since August 2021, now trading at around $58.75. The second quarter of 2024 (Q2) results beat expectations with revenue growth driven by the Cologuard screening segment. It raised adjusted EBITDA guidance for 2024, demonstrating confidence in continued sales momentum and profitability. It is likely to suffer from volatility risks as it continues to strike a balance between growth and profitability. The stock is a buy with a potential 27% upside also given the way it is improving its competitive position and leveraging AI for accelerating data analysis. Read the full article on Seeking AlphaSeeking Alpha • Jun 11
Exact Sciences: Still No Reason To Own
Summary We are revisiting oncology testing company Exact Sciences Corporation today for the first time in nearly a year and a half. The shares have been cut by more than half since last summer, despite revenue growth in the low teens and strong support from the analyst firm community. Is it time to buy the dip? An updated analysis around Exact Sciences follows in the paragraphs below. Read the full article on Seeking AlphaRentabilidad de los accionistas
| EXAS | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 0.9% | 1.5% | 1.5% |
| 1Y | 129.7% | 41.7% | 25.5% |
Rentabilidad vs. Industria: EXAS superó a la industria US Biotechs, que obtuvo un rendimiento del 41.7% el año pasado.
Rentabilidad vs. Mercado: EXAS superó al mercado US, que obtuvo un rendimiento del 25.5% el año pasado.
Volatilidad de los precios
| EXAS volatility | |
|---|---|
| EXAS Average Weekly Movement | 0.5% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: EXAS no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de EXAS ha disminuido de 6% a 0% en el último año.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1995 | 7,150 | n/a | www.exactsciences.com |
Exact Sciences Corporation suministra productos para pruebas de detección y diagnóstico del cáncer en Estados Unidos e internacionalmente. Ofrece Cologuard, una prueba de cribado de ADN no invasiva basada en heces para detectar biomarcadores de ADN y hemoglobina asociados al cáncer y precáncer colorrectal; Cologuard Plus Tests; Cancerguard Test; y Genetic Testing. La empresa también ofrece las pruebas Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; Oncodetect Test;OncoExTra Test para la elaboración de perfiles tumorales en pacientes con cáncer avanzado, metastásico, refractario, recidivante o recurrente; y Riskguard Test, una prueba de cáncer hereditario para conocer el riesgo hereditario de cáncer.
Resumen de fundamentos de Exact Sciences Corporation
| Estadísticas fundamentales de EXAS | |
|---|---|
| Capitalización bursátil | US$20.03b |
| Beneficios(TTM) | -US$207.95m |
| Ingresos (TTM) | US$3.25b |
6.2x
Ratio precio-ventas (PS)-96.3x
Ratio precio-beneficio (PE)¿Está EXAS sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de EXAS | |
|---|---|
| Ingresos | US$3.25b |
| Coste de los ingresos | US$984.15m |
| Beneficio bruto | US$2.26b |
| Otros gastos | US$2.47b |
| Beneficios | -US$207.95m |
Últimos beneficios comunicados
Dec 31, 2025
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.09 |
| Margen bruto | 69.69% |
| Margen de beneficio neto | -6.40% |
| Ratio deuda/patrimonio | 96.9% |
¿Cómo se ha desempeñado EXAS a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/03/24 11:24 |
| Precio de las acciones al final del día | 2026/03/20 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Exact Sciences Corporation está cubierta por 27 analistas. 12 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Bruce Jackson | Benchmark Company |
| Raymond Myers | Benchmark Company |